These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 23689905)

  • 1. Eculizumab and recurrent C3 glomerulonephritis.
    Gurkan S; Fyfe B; Weiss L; Xiao X; Zhang Y; Smith RJ
    Pediatr Nephrol; 2013 Oct; 28(10):1975-81. PubMed ID: 23689905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab for dense deposit disease and C3 glomerulonephritis.
    Bomback AS; Smith RJ; Barile GR; Zhang Y; Heher EC; Herlitz L; Stokes MB; Markowitz GS; D'Agati VD; Canetta PA; Radhakrishnan J; Appel GB
    Clin J Am Soc Nephrol; 2012 May; 7(5):748-56. PubMed ID: 22403278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
    Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
    Garg N; Zhang Y; Nicholson-Weller A; Khankin EV; Borsa NG; Meyer NC; McDermott S; Stillman IE; Rennke HG; Smith RJ; Pavlakis M
    Nephrol Dial Transplant; 2018 Dec; 33(12):2260-2265. PubMed ID: 29370420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease.
    Tran CL; Sethi S; Murray D; Cramer CH; Sas DJ; Willrich M; Smith RJ; Fervenza FC
    Pediatr Nephrol; 2016 Apr; 31(4):683-7. PubMed ID: 26759144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3 glomerulopathy and eculizumab: a report on four paediatric cases.
    Lebreton C; Bacchetta J; Dijoud F; Bessenay L; Fremeaux-Bacchi V; Sellier-Leclerc AL
    Pediatr Nephrol; 2017 Jun; 32(6):1023-1028. PubMed ID: 28236143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathology after eculizumab in dense deposit disease and C3 GN.
    Herlitz LC; Bomback AS; Markowitz GS; Stokes MB; Smith RN; Colvin RB; Appel GB; D'Agati VD
    J Am Soc Nephrol; 2012 Jul; 23(7):1229-37. PubMed ID: 22677550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of C3 glomerulonephritis successfully treated with eculizumab.
    Payette A; Patey N; Dragon-Durey MA; Frémeaux-Bacchi V; Le Deist F; Lapeyraque AL
    Pediatr Nephrol; 2015 Jun; 30(6):1033-7. PubMed ID: 25796589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
    Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
    Regunathan-Shenk R; Avasare RS; Ahn W; Canetta PA; Cohen DJ; Appel GB; Bomback AS
    Am J Kidney Dis; 2019 Mar; 73(3):316-323. PubMed ID: 30413277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
    Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
    Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C3 glomerulonephritis with a severe crescentic phenotype.
    Ravindran A; Fervenza FC; Smith RJH; Sethi S
    Pediatr Nephrol; 2017 Sep; 32(9):1625-1633. PubMed ID: 28593446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.
    Ozkaya O; Nalcacioglu H; Tekcan D; Genc G; Meydan BC; Ozdemir BH; Baysal MK; Keceligil HT
    Pediatr Nephrol; 2014 Jul; 29(7):1283-7. PubMed ID: 24464478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab fails where eculizumab restores renal function in C3nef-related DDD.
    Rousset-Rouvière C; Cailliez M; Garaix F; Bruno D; Laurent D; Tsimaratos M
    Pediatr Nephrol; 2014 Jun; 29(6):1107-11. PubMed ID: 24408225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
    Sethi S; Fervenza FC; Zhang Y; Zand L; Vrana JA; Nasr SH; Theis JD; Dogan A; Smith RJ
    Kidney Int; 2012 Aug; 82(4):465-73. PubMed ID: 22673887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment.
    Kaartinen K; Martola L; Räisänen-Sokolowski A; Meri S
    Clin Immunol; 2018 Feb; 187():104-106. PubMed ID: 29097196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Treatment of Posttransplant Recurrent Complement C3 Glomerulopathy with Eculizumab.
    Sahin H; Gok Oguz E; Akoglu H; Atilgan G; Ulusal Okyay G; Karaveli Gursoy G; Kip Teymur T; Ertoy D; Canbakan B; Ayli MD
    Iran J Kidney Dis; 2018 Oct; 12(5):315-318. PubMed ID: 30367025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
    Le Quintrec M; Lapeyraque AL; Lionet A; Sellier-Leclerc AL; Delmas Y; Baudouin V; Daugas E; Decramer S; Tricot L; Cailliez M; Dubot P; Servais A; Mourey-Epron C; Pourcine F; Loirat C; Frémeaux-Bacchi V; Fakhouri F
    Am J Kidney Dis; 2018 Jul; 72(1):84-92. PubMed ID: 29429752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
    Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
    Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
    Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
    Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.